The DOI matches its Crossref record.
N‐acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain‐Barré syndrome
Abstract
Serum antibodies against such major glycolipids as GM1, GD1b, and LM1 have been reported in patients in the acute phase of Guillain‐Barré syndrome (GBS). Because minor unidentified glycolipids also may be targets of antibodies in GBS sera, we assayed serum antibody against a crude ganglioside fraction using thin‐layer chromatogram immunostaining. Antibody activity was detected against a band that migrated just below GD1a in 6 of the 50 patients with GBS tested. Antibody titer, as determined by enzyme‐linked immunosorbent assay, decreased during the course of the disease. All 6 patients had suffered gastrointestinal infection before the neurological onset of GBS and showed low amplitudes for the compound muscle action potentials and normal or only slightly decreased nerve conduction velocities. Thin‐layer chromatogram immunostaining did not show this antibody activity in any of the 16 normal and 119 disease controls. The unidentified glycolipid was isolated by DEAE–Sephadex A‐25 column chromatography, sialidase treatment, and Iatrobeads column chromatography. Fast atom bombardment‐mass spectra showed it to be N‐acetyl‐galactosaminyl GD1a.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Willison, H. J., Jacobs, B. C., & van Doorn, P. A. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00339-1 · Cited by 1,609
Peripheral neuropathies and anti-glycolipid antibodies
Willison, H. J. (2002) · Brain · doi:10.1093/brain/awf272 · Cited by 710
Campylobacter Species and Guillain-Barré Syndrome
Nachamkin, I., Allos, B. M., & Ho, T. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.3.555 · Cited by 590
Odaka, M., Yuki, N., Yamada, M., Koga, M., Takemi, T., Hirata, K., & Kuwabara, S. (2003) · Brain · doi:10.1093/brain/awg233 · Cited by 440
Pathogenesis of Guillain–Barré syndrome
Hughes, R. A. C., Hadden, R. D. M., Gregson, N. A., & Smith, K. J. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00195-2 · Cited by 405
Metadata
- Authors
- Kusunoki, S., Chiba, A., Kon, K., Ando, S., Arisawa, K., Tate, A., & Kanazawa, I.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 1994-05
- Volume
- 35
- Issue
- 5
- Pages
- 570-576
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2118206412
- Cited by
- 180
- References
- 0
- FWCI
- 6.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: N‐acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain‐Barré syndrome. https://app.cochat.ai/papers/10.1002/ana.410350510
- The paper
- Kusunoki, S., Chiba, A., Kon, K., Ando, S., Arisawa, K., Tate, A., & Kanazawa, I. (1994). N‐acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain‐Barré syndrome. Annals of Neurology. https://doi.org/10.1002/ana.410350510
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.